NCT03300427View on ClinicalTrials.gov

The Effects of Sacubitril/Valsartan on Cardiac Oxygen Consumption and Efficiency of Cardiac Work in Heart Failure Patients

PHASE4CompletedINTERVENTIONAL
Enrollment

55

Participants

Timeline

Start Date

July 5, 2018

Primary Completion Date

March 23, 2022

Study Completion Date

March 23, 2022

Conditions
Heart Failure
Interventions
DRUG

sacubitril/valsatran

sacubitril/valsatran 100 or 200 mg BID

DRUG

valsartan

Valsartan 80 or 160 mg BID

DRUG

placebo to valsartan

placebo to valsartan 80 or 160 BID

DRUG

placebo to sacubitril/valsartan

placebo to sacubitril/valsartan 100 or 200 mg BID

Trial Locations (1)

20521

Novartis Investigative Site, Turku

Sponsors
All Listed Sponsors
lead

Novartis Pharmaceuticals

INDUSTRY